1La Rovere MT, Pinna GD, Maestri R, et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era[J]. J Am Coll Cardiol, 2009,53(2) : 193-199.
2Guyenet PG. The sympathetic control of blood pressure[J]. Nat Rev Neurosci, 2006, 7(5): 335-346.
3Farmakis D, Filippatos G, Kremastinos DT,et al. Vasopressin and vasopressin antagonists in heart failure and hyponatremia[J]. Curr Heart Fail Rep, 2008,5(2):91-96.
4Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress[J]. Med Clin North Am, 2009,93 (3): 569-582.
5Zucker IH, Schultz HD, Patel KP, et al. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure[J]. Am J Physiol, 2009,297(5) : H1557-H1566.
6Heusser K, Tank J, Engeli S, et al. Carotid baroreeeptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients [J]. Hypertension, 2010,55(3) :619-626.
7Lu Y, Ma X, Sabharwal R, et al. The ion channel ASIC2 is required for baroreceptor and autonomic control of the circulation[J]. Neuron, 2009,64(6) :885-897.
8Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial[J]. J Am Soc Hypertens, 2012, 6(4) : 270-276.
9Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study [J ]. J Am Cull Cardiol, 2010,56(15) : 1254-1258.
10Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial[J]. J Am Coil Cardiol, 2011,58(7) :765-773.
